Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations
- 1 November 2024
- journal article
- review article
- Published by Taylor & Francis in Pharmaceutical Patent Analyst
- Vol. 13 (4-6) , 187-199
Abstract
Proteolysis Targeting Chimeras (PROTACs) represents a groundbreaking advancement in drug discovery and targeted protein degradation. Unlike traditional small-molecule inhibitors, PROTACs leverage the cell's natural protein degradation machinery to selectively degrade pathogenic proteins, offering significant therapeutic potential for previously undruggable targets and complex diseases such as cancer and neurodegenerative disorders. Understanding the regulatory landscape governing their approval is crucial as their development accelerates. This review provides an overview of recent patents, regulatory considerations, emerging concerns, and future perspectives of PROTACs in cancer management. From a regulatory perspective, PROTACs present unique challenges and opportunities. Their dual-functional nature requires a nuanced approach to classification and approval, blending small-molecule and biologic regulatory frameworks. Specific guidelines addressing pharmacokinetic and pharmacodynamic profiles are needed. Comprehensive preclinical evaluation and robust clinical trial designs are essential to manage off-target effects and immunogenic responses. The collaboration between regulatory bodies, academia, and industry is crucial for establishing a clear pathway for PROTAC approval. Future considerations must account for advancements in PROTAC technology to ensure safe and effective therapies reach patients. While PROTACs hold immense promise, their regulatory journey requires tailored guidelines and rigorous evaluation to realize their full potential.Keywords
This publication has 37 references indexed in Scilit:
- Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and IndiaEuropean Journal of Pharmaceutics and Biopharmaceutics, 2024
- Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscapeEuropean Journal of Pharmaceutics and Biopharmaceutics, 2024
- The cyclimids: Degron-inspired cereblon binders for targeted protein degradationCell Chemical Biology, 2024
- What influences the activity of Degrader−Antibody conjugates (DACs)European Journal of Medicinal Chemistry, 2024
- Expanding the horizons of targeted protein degradation: A non-small molecule perspectiveActa Pharmaceutica Sinica B, 2024
- Immunogenicity risk assessment of synthetic peptide drugs and their impuritiesDrug Discovery Today, 2023
- Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs)Drug Discovery Today, 2022
- First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivoEuropean Journal of Medicinal Chemistry, 2021
- The PROTAC technology in drug developmentCell Biochemistry and Function, 2019
- Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugsEBioMedicine, 2018